Autosomal Recessive Osteopetrosis 1 (ARO1)

Autosomal recessive osteopetrosis 1 (ARO1) is a severe genetic bone disease usually starting in infancy. It is caused most often by harmful changes in the TCIRG1 gene, which makes a key part of the acid pump (V-ATPase) that osteoclast cells need to hollow out bone. When osteoclasts cannot work, bones become very dense but brittle, bone marrow space is crowded out (causing anemia? and infections), and tight skull openings can compress nerves (vision and hearing problems). Without effective treatment, serious illness and early death are common; hematopoietic stem-cell transplantation (HSCT) is the only proven curative option for the osteoclast defect. NCBI+1

Autosomal recessive osteopetrosis 1 is a severe, inherited bone disease that starts in infancy. In this condition, the cells that normally remove old bone (osteoclasts) do not work properly. Because removal is blocked while new bone keeps forming, bones become abnormally dense and heavy but also brittle, the marrow spaces narrow or close, and nerves that pass through tiny holes in skull bones can be squeezed. Babies and young children may develop anemia? (low blood cells), enlarged liver and spleen, poor growth, frequent fractures, vision or hearing problems, and low calcium with seizures. ARO1 is caused by harmful changes in the TCIRG1 gene, which encodes the a3 subunit of the vacuolar proton pump (V-ATPase) that osteoclasts need to acidify and dissolve bone. NCBI+2MedlinePlus+2

Other names

Doctors and articles may use several labels for the same disease. These include “autosomal recessive malignant? osteopetrosis,” “malignant infantile osteopetrosis,” “OPTB1,” “ARO1,” and “TCIRG1-related osteopetrosis.” They all refer to the severe infantile form caused by harmful variants in TCIRG1. (“Albers-Schönberg disease” is sometimes used historically for osteopetrosis in general, but modern usage reserves it mainly for other forms; context matters.) NCBI+2NCBI+2

Types

“Osteopetrosis” is an umbrella term. There are several genetic types. ARO1 is the TCIRG1-related infantile form. Other autosomal recessive forms can be caused by CLCN7, OSTM1, SNX10, PLEKHM1, TNFSF11 (RANKL), TNFRSF11A (RANK), CA2, and a few additional rare genes. Across all severe recessive cases, TCIRG1 variants account for roughly half—which is why the label “ARO1” is common in infants. Autosomal dominant osteopetrosis (ADO) is different, usually milder, and most often due to CLCN7 variants. MedlinePlus+2BioMed Central+2

Doctors group osteopetrosis by inheritance pattern and severity:

1. Autosomal recessive (ARO, infantile malignant?) — severe, starts in infancy. ARO is genetically heterogeneous; the most common cause is TCIRG1 (ARO1); other ARO genes include CLCN7, OSTM1, SNX10, PLEKHM1, TNFRSF11A (RANK), TNFSF11 (RANKL), CA2, and a few more rare genes. MedlinePlus+2BioMed Central+2

2. Autosomal dominant (ADO, “adult” or Albers-Schönberg) — milder, often found in teens/adults, commonly due to CLCN7. NCBI

3. Intermediate autosomal osteopetrosis (IAO) — severity between ARO and ADO. NCBI

This article focuses on ARO1 (TCIRG1-related ARO). TCIRG1 defects account for ~50% of ARO cases worldwide. MedlinePlus+1

Causes

In simple terms, the cause of ARO1 is harmful changes in the TCIRG1 gene that break the acid pump osteoclasts use to dissolve bone. Below are 20 closely related “causes” and mechanisms that explain how and why disease happens or who is at risk:

1. Biallelic TCIRG1 variants (mutations) — you must inherit one faulty copy from each parent for disease to appear. NCBI

2. Loss-of-function variants (nonsense, frameshift, large deletions) — remove the a3 subunit and abolish pump activity. Nature

3. Missense variants — swap one amino acid and destabilize or mis-target the a3 subunit. Nature

4. Splice-site / intronic variants — create incorrect RNA and a defective protein; even “hypomorphic” splice changes can yield milder disease. Nature

5. Compound heterozygosity — two different TCIRG1 variants (one from each parent) combine to cause disease. Frontiers

6. Founder variants in certain communities — repeated ancestry increases the frequency of a specific TCIRG1 change. BioMed Central

7. Parental consanguinity — increases the chance both parents carry the same rare variant. BioMed Central

8. Defective osteoclast acidification — with a broken V-ATPase, osteoclasts cannot acidify the resorption lacuna, so mineral does not dissolve. MedlinePlus

9. Failure to form/maintain the ruffled border at the osteoclast-bone interface, further blocking bone resorption. BioMed Central

10. Osteoclast-rich but functionally inactive phenotype — osteoclasts are present yet ineffective. ScienceDirect

11. Accumulation of primary spongiosa — unresorbed cartilage?/bone fills marrow cavities, crowding out blood formation. PMC

12. Narrowed cranial foramina from excess bone growth cause nerve compression (optic, auditory, facial). PMC

13. Secondary bone marrow failure — closed marrow spaces lead to anemia?, low platelets, and infections. National Organization for Rare Disorders

14. Disordered calcium balance — impaired remodeling contributes to hypocalcemia and sometimes seizures (“osteopetrorickets”). NCBI

15. Modifier genes — variation in other bone or immune genes can alter severity even with the same TCIRG1 variants. ScienceDirect

16. Environmental/health modifiers (e.g., malnutrition, intercurrent illness) — can worsen growth failure and infections in ARO infants. National Organization for Rare Disorders

17. Delayed diagnosis? — not a root cause, but allows progressive bone overgrowth and nerve damage to continue unchecked. PMC

18. Heterogeneity within TCIRG1 — different variant locations (including deep intronic changes) can produce mild to very severe disease. Nature

19. Rare dominant-acting TCIRG1 variants reported in families — illustrates that the same gene can occasionally act differently, though ARO1 is classically recessive. NCBI

20. Gene-level mosaicism in a parent — uncommon, but can explain recurrence in families with negative standard carrier tests. (Inference from general Mendelian genetics; clinicians consider this when results don’t fit.) BioMed Central

Symptoms and signs

1. Poor growth and weight gain in infancy because illness, infections, and feeding difficulty steal energy. NCBI

2. Frontal bossing and enlarged head (macrocephaly) from abnormal skull bone growth. Myriad Genetics

3. Dense but fragile bones with frequent fractures after minor falls; density does not equal strength. BioMed Central

4. Bone pain? and limping gait from crowded, rigid bones and micro-fractures. NCBI

5. Pale skin and fatigue? due to anemia? (marrow failure). National Organization for Rare Disorders

6. Easy bruising or nosebleeds from low platelets. National Organization for Rare Disorders

7. Frequent or severe infections because white blood cells are low or function poorly when marrow is crowded. National Organization for Rare Disorders

8. Big belly from enlarged liver and spleen (hepatosplenomegaly) that try to make blood outside the marrow. National Organization for Rare Disorders

9. Vision problems (reduced vision, nystagmus) when the optic nerves are compressed by narrowed skull canals. PMC

10. Hearing loss from compression of the auditory nerves and changes in the middle ear bones. PMC

11. Delayed tooth eruption and many cavities, sometimes jaw osteonecrosis, because bone around teeth is abnormal. NCBI

12. Low calcium symptoms — jitteriness, muscle cramps, or seizures in infancy. NCBI

13. Enlarged fontanelle or, less often, early closure depending on mineralization; skull growth can be abnormal either way. NCBI

14. Short stature over time from disordered growth plates and illness burden. BioMed Central

15. Developmental delays (often secondary) due to vision/hearing loss, illness, and hospitalizations. National Organization for Rare Disorders

Diagnostic tests

A) Physical examination

1. Full growth and nutrition check — weight, length/height, and head size help flag early failure to thrive and macrocephaly. NCBI

2. Bone and joint exam — pain? when an area is touched or pressed. সহজ বাংলা: চাপ দিলে ব্যথা।" data-rx-term="tenderness" data-rx-definition="Tenderness means pain when an area is touched or pressed. সহজ বাংলা: চাপ দিলে ব্যথা।">tenderness?, deformities, bowed legs, or limp suggest fractures or bone pain. PMC

3. Eye exam with light and fundus check — looks for optic nerve pallor and nystagmus from nerve compression. PMC

4. Ear and hearing-related bedside checks — gross hearing response guides need for formal tests. PMC

5. Abdomen exam — feeling enlarged liver and spleen supports marrow failure with “extra-medullary” blood-making. National Organization for Rare Disorders

B) Manual/bedside functional tests

6. Developmental screening? (simple play and movement tasks) to see if vision, hearing, and motor skills are affected. National Organization for Rare Disorders

7. Bedside vision checks (fix-and-follow, pupillary responses) to detect optic nerve involvement early. PMC

8. Bedside hearing screening? (oto-acoustic emissions in infants) as a quick check before formal audiology. PMC

9. Dental examination — counts erupted teeth, checks for caries and jaw pain? when an area is touched or pressed. সহজ বাংলা: চাপ দিলে ব্যথা।" data-rx-term="tenderness" data-rx-definition="Tenderness means pain when an area is touched or pressed. সহজ বাংলা: চাপ দিলে ব্যথা।">tenderness? due to dense, poorly vascular bone. NCBI

10. Neurologic cranial nerve exam — facial movement, eye movements, and swallowing help localize skull-base compression. PMC

C) Laboratory and pathological tests

11. Complete blood count (CBC) — often shows anemia?, low platelets, and sometimes low neutrophils from marrow crowding. National Organization for Rare Disorders

12. Chemistry panel with calcium, phosphate, alkaline phosphatase, PTH, vitamin D — may show low calcium with secondary hyperparathyroidism (“osteopetrorickets”). NCBI

13. Peripheral blood smear — looks for immature cells when marrow fails and blood-making shifts to liver/spleen. National Organization for Rare Disorders

14. Genetic testing of TCIRG1 (single-gene or panel) — confirms ARO1 by finding two pathogenic variants; panels also check other ARO genes. Myriad Genetics+1

15. Bone marrow aspirate/biopsy? (when needed) — shows reduced normal marrow and sometimes osteoclasts that are present but ineffective. PMC

16. Electrolytes/acid-base when CA2-like features suspected — helps rule in/out rare osteopetrosis with renal? tubular acidosis (a different gene). (Differential context.) ScienceDirect

D) Electrodiagnostic and neuro-sensory tests

17. Visual evoked potentials (VEP) — measures the brain’s response to visual signals and detects optic nerve compression early. PMC

18. Brainstem auditory evoked responses (BAER/ABR) — checks hearing nerve conduction through thickened skull bone. PMC

19. Nerve conduction studies/EMG (selected cases) — assess peripheral nerve compression or secondary pain?, numbness?, tingling, or weakness?. সহজ বাংলা: স্নায়ুর ক্ষতি/সমস্যা।" data-rx-term="neuropathy" data-rx-definition="Neuropathy means nerve damage or irritation causing pain, numbness, tingling, or weakness. সহজ বাংলা: স্নায়ুর ক্ষতি/সমস্যা।">neuropathy? from rigid bone canals. PMC

20. Formal audiology (age-appropriate) — quantifies hearing loss to guide devices and timing of interventions. PMC

E) Imaging tests (what pictures show)

21. Plain X-rays (skeletal survey) — the key first study: diffuse increased bone density, “bone-within-bone” appearance, “sandwich vertebrae”, and Erlenmeyer-flask long bones are typical. PMC

22. Head CT — shows narrowed skull base foramina that explain optic and auditory nerve problems. PMC

23. MRI of brain/orbits — evaluates optic nerves and soft tissues when vision is threatened. PMC

24. Ultrasound? (prenatal or infant) — can detect unusually bright, dense bones before birth or early in life. BioMed Central

25. DXA (bone density scan) — less helpful for diagnosis? (everything looks dense), but sometimes used to follow changes over time. BioMed Central

Non-pharmacological treatments (high-impact options)

1) Early referral for HSCT (curative intent).
HSCT replaces the child’s non-working osteoclast lineage with donor cells that can resorb bone. Best outcomes occur when done early (ideally before 10–12 months), before irreversible nerve injury. Five-year disease-free survival in expert centers is high with HLA-matched donors; careful monitoring is needed for post-transplant complications like hypercalcemia, VOD, pulmonary hypertension?, and infection?. NCBI+2PMC+2

2) Bridge therapy and timing.
Because donor search and transplant setup take time, teams often use supportive care (and, when appropriate, interferon-γ1b—see Drug #1 below) to stabilize bone-marrow function and reduce complications while HSCT is arranged. Early action improves vision and survival chances. NCBI

3) Multidisciplinary care plan.
Children need coordinated specialists (hematology, endocrinology, orthopedics, neurosurgery, ophthalmology, audiology, dentistry, PT/OT). This team manages fractures, anemia?, infections, vision/hearing risks, and dental disease. NCBI

4) Fracture? prevention and safe mobility.
Use fall-proofing at home, protective gear, safe transfers, low-impact mobility training, and assistive devices. Osteopetrotic bone is hard to drill and fix; avoiding fractures is crucial. NCBI

5) Physical and occupational therapy.
Gentle strengthening, balance, and posture programs help mobility and reduce falls without stressing brittle bones. Therapists also provide home safety and equipment advice. NCBI

6) Dental and jaw care.
Strict oral hygiene, early dental evaluation, and cautious extractions are important to avoid osteomyelitis of the mandible, which is a known risk in osteopetrosis. BioMed Central

7) Vision protection and surveillance.
Frequent eye checks (visual acuity, fields, OCT, VEP). When optic canals are tight and vision declines, optic nerve decompression can help selected patients (see Surgery below). PMC+2Journal of Neurosurgery+2

8) Hearing and airway monitoring.
Assess for conductive hearing loss and crowded airways; involve ENT for ventilation, hearing aids, or airway support when needed. NCBI

9) Nutrition with careful calcium/vitamin-D targets.
Aim for normal vitamin-D status (25-OH D >30 ng/mL). Some centers consider modest calcium restriction in selected patients, but calcium may be required if hypocalcemia or rickets develops—so this must be individualized and monitored. High-dose calcitriol is generally not recommended outside specific indications per consensus guidance. Medscape

10) Vaccination and infection?-prevention routines.
Keep routine immunizations up-to-date and practice infection? prevention (hand hygiene, dental care, prompt treatment of skin and dental infections) because marrow crowding can reduce immune reserve. NCBI

Drug treatments

Important: Only interferon-γ1b has an FDA-approved indication specifically for severe, malignant? osteopetrosis. All other medicines below are supportive/off-label and should be used by specialists with close monitoring. FDA Access Data

Drug 1. Interferon-γ1b (ACTIMMUNE®) — the only FDA-approved drug in SMO/ARO

• What it is / purpose: A lab-made version of interferon-γ that can stimulate immune cells and promote some bone resorption, used to delay disease progression in severe malignant? osteopetrosis and often as a bridge to HSCT. FDA Access Data+1

• Dose & timing (FDA label): Subcutaneous 50 mcg/m² (if BSA >0.5 m²) or 1.5 mcg/kg/dose (if BSA ≤0.5 m²) three times weekly (e.g., Mon/Wed/Fri). Monitor labs before therapy and every 3 months (liver monthly if <1 year old). FDA Access Data

• Mechanism (simple): Boosts immune function and can enhance osteoclast activity in some forms of osteopetrosis. BioMed Central

• Key side effects / cautions: Flu-like symptoms, liver enzyme elevations (need monitoring), bone-marrow suppression (watch neutrophils/platelets), potential neuro/cardiac toxicity, and hypersensitivity. Dose-reduce or hold for severe reactions. FDA Access Data

Drug 2. Vitamin D3 (cholecalciferol) ± ergocalciferol

• Purpose & mechanism: Correct vitamin-D deficiency to support calcium balance and bone health; target serum 25-OH D >30 ng/mL. Not a disease cure; helps prevent rickets/hypocalcemia that can worsen bone pain? and fractures. Medscape

Drug 3. Calcitriol (active vitamin D)

• Purpose & mechanism: In specific cases of hypocalcemia/osteopetrorickets, active vitamin D can raise calcium and support mineralization. High-dose calcitriol is not routinely recommended in osteopetrosis outside defined indications. Medscape

Drug 4. Calcium (individualized)

• Purpose & mechanism: Treat symptomatic hypocalcemia; dose only with clear biochemical need and monitoring to avoid over-supplementation that could aggravate problems. Medscape

Drug 5. Red-blood-cell transfusions / Erythropoiesis-stimulating agents (e.g., epoetin alfa)

• Purpose & mechanism: Relieve symptomatic anemia from marrow crowding; ESAs may be considered case-by-case to stimulate RBC production. (Supportive strategy; not disease-modifying.) Medscape

Drug 6. Granulocyte colony-stimulating factor (filgrastim) during severe neutropenia

• Purpose & mechanism: Boost neutrophils in infection-prone periods pre-/post-HSCT if needed, under hematology guidance. (Supportive; evidence is extrapolated.) NCBI

Drug 7. Broad-spectrum antibiotics for osteomyelitis and dental infections

• Purpose & mechanism: Prompt, culture-guided therapy for jaw and long-bone infections common in osteopetrosis; antibiotics are critical adjuncts with dental/surgical care. BioMed Central

Drug 8. Calcitonin for post-HSCT hypercalcemia

• Purpose & mechanism: After HSCT, rapid osteoclast engraftment can cause rebound hypercalcemia; short-term calcitonin (with fluids/loop diuretics) helps lower calcium safely. Medscape

(Note: Other classes—analgesics for fracture pain; anticonvulsants if seizures are unrelated to calcium; antifungals/antivirals as needed—are individualized supportive therapies. Bisphosphonates/denosumab are generally not used because they further suppress osteoclasts, which is the core problem in ARO; management should be specialist-led.) BioMed Central

Dietary molecular supplements (supportive, individualized)

Supplements should be supervised by the care team; many children need lab-guided adjustments. Evidence is supportive/physiologic rather than disease-curative.

1) Vitamin D3 to keep 25-OH D >30 ng/mL; improves calcium handling and reduces rickets risk. Medscape

2) Calcium only if dietary intake is low or hypocalcemia is documented; avoid routine high doses. Medscape

3) Balanced protein (adequate calories) to support growth, wound healing after fractures/surgery, and immune function during HSCT. NCBI

4) Iron (if iron-deficient) under hematology guidance to support erythropoiesis and reduce transfusion needs. NCBI

5) Folate/B12 if deficient, to support marrow function (screen first; don’t supplement blindly). NCBI

6) Omega-3 fatty acids (nutrition support) for general anti-inflammatory balance and cardiovascular health during long care courses. (Adjunctive rationale.) NCBI

7) Magnesium if low; stabilizes neuromuscular function and calcium balance. NCBI

8) Zinc if deficient; supports wound healing and immunity during frequent procedures. NCBI

9) Multivitamin without excess vitamin A to avoid hypervitaminosis-A skeletal effects; aim for age-appropriate RDAs. NCBI

10) Oral hydration plans to help prevent constipation on pain meds and support calcium management. Medscape

Immune-support / regenerative / stem-cell drug concepts

1) Hematopoietic stem-cell transplantation (HSCT) (clinical standard)
Transplantation is the disease-modifying option for TCIRG1-related ARO, replacing the osteoclast lineage and allowing bone remodeling and marrow recovery. Early HSCT improves outcomes; it does not reverse all pre-existing nerve damage, so timing matters. NCBI+1

2) Haploidentical HSCT with post-transplant cyclophosphamide (when matched donor unavailable)
Modern haplo protocols have broadened access to transplant with acceptable outcomes in experienced centers, though graft failure risk is higher than with matched donors. Medscape

3) Donor-derived osteoclast engraftment (mechanistic point)
Even partial chimerism may correct marrow failure; clinicians watch for post-HSCT hypercalcemia as a sign of active osteoclasts. PubMed+1

4) Interferon-γ1b as bridge (immune-modulating)
Used pre-HSCT to stabilize marrow and possibly enhance bone turnover; FDA-approved to delay progression in severe malignant osteopetrosis. Not curative alone. FDA Access Data+1

5) Experimental gene-therapy approaches (preclinical/early translational).
Research explores gene correction of osteoclast precursors (e.g., ex-vivo corrected HSCs). These are not yet standard of care and should be pursued only via clinical trials. ResearchGate

6) Supportive immunization and infection control.
Routine vaccines and infection-prevention protocols protect limited marrow reserve during the treatment journey. NCBI

Surgeries and procedures

1) Optic nerve decompression.
For progressive visual loss from bony canal narrowing, decompression—via endoscopic endonasal, transcaruncular, or craniotomy approaches—can improve or preserve vision when done early in selected cases; long-term stability varies, and decisions are case-by-case with experienced teams. Karger Publishers+3PMC+3PubMed+3

2) Fracture fixation and deformity correction.
Orthopedic teams plan carefully because bone is very hard and prone to iatrogenic fracture; fixation strategy is individualized, often favoring robust mechanical support and meticulous technique. Medscape

3) Cranial foraminal decompressions beyond optic canal (selected).
In severe skull base crowding with nerve compression (e.g., hearing/cranial neuropathies), targeted decompression may be considered by neurosurgery. BioMed Central

4) CSF shunting for hydrocephalus (if present).
Raised intracranial pressure from narrowed skull foramina can require shunt placement in selected cases. BioMed Central

5) Dental surgery with infection control.
Extractions and jaw procedures use antibiotic prophylaxis and careful technique to reduce osteomyelitis risk. BioMed Central

Prevention tips

1. Start transplant evaluation early to avoid irreversible nerve damage. NCBI

2. Fall-proof the home and use assistive devices to prevent fractures. NCBI

3. Keep vaccines current and seek prompt care for infections. NCBI

4. Routine eye/hearing checks to catch compression early. PMC

5. Good dental hygiene and regular dentist visits. BioMed Central

6. Balanced vitamin-D and calcium with lab monitoring; avoid unmonitored megadoses. Medscape

7. Use child-safe mobility strategies; avoid high-impact sports. NCBI

8. Plan surgeries with centers experienced in osteopetrosis (bone handling is unique). Medscape

9. Maintain good nutrition and hydration to support growth and healing. Medscape

10. Keep all specialist appointments (hematology, endocrinology, ophthalmology, orthopedics, dentistry). NCBI

When to see a doctor urgently

See your care team or emergency services immediately for: new or worsening vision problems (reduced acuity, visual field loss), severe headache or vomiting (possible raised intracranial pressure), fever or suspected infection, painful swelling in the jaw (possible osteomyelitis), fractures or severe bone pain, seizures or tetany (possible hypocalcemia), or any post-HSCT symptom like high fever, breathing trouble, jaundice, or signs of dehydration/hypercalcemia. NCBI+1

What to eat / what to avoid

• Aim for balanced meals with adequate protein, fruits/vegetables, and age-appropriate calories to support growth and recovery. NCBI

• Vitamin D (dietary + sensible sunlight) and calcium intake should meet needs, but large supplements should only be taken if labs show a need. Medscape

• Stay well hydrated, especially around surgeries and during HSCT. Medscape

• Avoid excess vitamin A and unregulated “bone” supplements; they can harm bone or interact with treatments. NCBI

• Avoid high-risk choking foods and hard-crunch items if dental fragility is present. BioMed Central

FAQs

1) Is ARO1 the same as “malignant infantile osteopetrosis”?
Yes. TCIRG1-related autosomal recessive osteopetrosis is often called “malignant infantile osteopetrosis,” reflecting its severity and early onset. NCBI

2) What makes ARO1 different from other osteopetroses?
ARO1 is caused by TCIRG1 variants (~58% of AR cases) affecting the osteoclast acid pump; other AR types involve genes like CLCN7, OSTM1, SNX10. NCBI

3) Can medicines cure ARO1?
No. Only HSCT can correct the underlying osteoclast defect. Interferon-γ1b may slow progression and is often used while preparing for HSCT. NCBI+1

4) Will HSCT restore vision or hearing?
It can prevent further damage, but established nerve injury often persists. Up to 70% of survivors still have some visual impairment; hence early referral is vital. NCBI

5) Is optic nerve decompression surgery helpful?
In carefully selected patients with early compression, decompression may improve or preserve vision; benefits depend on timing and anatomy. PMC+1

6) Why avoid high-dose calcitriol?
Consensus guidance notes uncertain benefit and potential risks; vitamin-D plans should be targeted to lab values. Medscape

7) Why are fractures common if the bones are “dense”?
Density does not equal strength. Osteoclast failure leads to abnormal architecture—dense but brittle bone that breaks easily. NCBI

8) Are gene therapies available?
Not yet for routine care. Gene-correction strategies are under research and should only be pursued in clinical trials. ResearchGate

9) What labs should be checked regularly?
Calcium, phosphorus, 25-OH vitamin D, PTH, and complete blood counts (and more often if on calcitriol or interferon-γ1b). Medscape+1

10) Is ARO1 common?
No. AR osteopetrosis overall occurs in about 1 in 250,000 births; TCIRG1 variants account for the majority of AR cases. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 12, 2025.